Tanja Meyer

Tanja Meyer

Auto-generated profile, based on publicly available information

Tanja Meyer

Centre for Biological Threats and Special Pathogens, ZBS3 Biological Toxins, Robert Koch Institute, Berlin, Germany

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SMStephan Michalik
Stephan Michalik
MDMaren Depke
Maren Depke
AMAnnette Murr
Annette Murr
MSManuela Gesell Salazar
Manuela Gesell Salazar
UKUlrike Kusebauch
Ulrike Kusebauch
FSFrank Schmidt
Frank Schmidt
Data-independent acquisition mass spectrometry promises higher performance in terms of quantification and reproducibility compared to data-dependent acquisition mass spectrometry methods. To enable high-accuracy quantification of Staphylococcus aureus proteins, we have developed a global ion library for data-independent acquisition approaches employing high-resolution time of flight or Orbitrap instruments for this human pathogen. We applied this ion library resource to investigate the time-resolved adaptation of S. aureus to the intracellular niche in human bronchial epithelial cells and in a murine pneumonia model. In epithelial cells, abundance changes for more than 400 S. aureus proteins were quantified, revealing, e.g., the precise temporal regulation of the SigB-dependent stress response and differential regulation of translation, fermentation, and amino acid biosynthesis. Using an in vivo murine pneumonia model, our data-independent acquisition quantification analysis revealed for the first time the in vivo proteome adaptation of S. aureus. From approximately 2.15 × 105 S. aureus cells, 578 proteins were identified. Increased abundance of proteins required for oxidative stress response, amino acid biosynthesis, and fermentation together with decreased abundance of ribosomal proteins and nucleotide reductase NrdEF was observed in post-infection samples compared to the pre-infection state.

18 October 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
FVFranziska Voß
Franziska Voß
TKThomas P. Kohler
Thomas P. Kohler
TMTanja Meyer
Tanja Meyer
MAMohammed R. Abdullah
Mohammed R. Abdullah
FOFred J. van Opzeeland
Fred J. van Opzeeland
Sven HammerschmidtSven Hammerschmidt
Sven Hammerschmidt
Streptococcus pneumoniae is endowed with a variety of surface-exposed proteins representing putative vaccine candidates. Lipoproteins are covalently anchored to the cell membrane and highly conserved among pneumococcal serotypes. Here, we evaluated these lipoproteins for their immunogenicity and protective potential against pneumococcal colonisation. A multiplex-based immunoproteomics approach revealed the immunogenicity of selected lipoproteins. High antibody titres were measured in sera from mice immunised with the lipoproteins MetQ, PnrA, PsaA, and DacB. An analysis of convalescent patient sera confirmed the immunogenicity of these lipoproteins. Examining the surface localisation and accessibility of the lipoproteins using flow cytometry indicated that PnrA and DacB were highly abundant on the surface of the bacteria. Mice were immunised intranasally with PnrA, DacB, and MetQ using cholera toxin subunit B (CTB) as an adjuvant, followed by an intranasal challenge with S. pneumoniae D39. PnrA protected the mice from pneumococcal colonisation. For the immunisation with DacB and MetQ, a trend in reducing the bacterial load could be observed, although this effect was not statistically significant. The reduction in bacterial colonisation was correlated with the increased production of antigen-specific IL-17A in the nasal cavity. Immunisation induced high systemic IgG levels with a predominance for the IgG1 isotype, except for DacB, where IgG levels were substantially lower compared to MetQ and PnrA. Our results indicate that lipoproteins are interesting targets for future vaccine strategies as they are highly conserved, abundant, and immunogenic.

1 February 2017 in Journal of Proteomics
Verified
Journal Article
Closed access
FSFrank Schmidt
Frank Schmidt
TMTanja Meyer
Tanja Meyer
NSNandakumar Sundaramoorthy
Nandakumar Sundaramoorthy
SMStephan Michalik
Stephan Michalik
KSKristin Surmann
Kristin Surmann
UVUwe Volker
Uwe Volker

29 July 2019 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
FSFrank Schmidt
Frank Schmidt
NKNiamatullah Kakar
Niamatullah Kakar
TMTanja C. Meyer
Tanja C. Meyer
MDMaren Depke
Maren Depke
IMIlias Masouris
Ilias Masouris
Sven HammerschmidtSven Hammerschmidt
Sven Hammerschmidt
Streptococcus pneumoniae (pneumococci) is a leading cause of severe bacterial meningitis in many countries worldwide. To characterize the repertoire of fitness and virulence factors predominantly expressed during meningitis we performed niche-specific analysis of the in vivo proteome in a mouse meningitis model, in which bacteria are directly inoculated into the cerebrospinal fluid (CSF) cisterna magna. We generated a comprehensive mass spectrometry (MS) spectra library enabling bacterial proteome analysis even in the presence of eukaryotic proteins. We recovered 200,000 pneumococci from CSF obtained from meningitis mice and by MS we identified 685 pneumococci proteins in samples from in vitro filter controls and 249 in CSF isolates. Strikingly, the regulatory two-component system ComDE and substrate-binding protein AliB of the oligopeptide transporter system were exclusively detected in pneumococci recovered from the CSF. In the mouse meningitis model, AliB-, ComDE-, or AliB-ComDE-deficiency resulted in attenuated meningeal inflammation and disease severity when compared to wild-type pneumococci indicating the crucial role of ComDE and AliB in pneumococcal meningitis. In conclusion, we show here mechanisms of pneumococcal adaptation to a defined host compartment by a proteome-based approach. Further, this study provides the basis of a promising strategy for the identification of protein antigens critical for invasive disease caused by pneumococci and other meningeal pathogens. Pneumococci are one of the most common and aggressive meningitis pathogens associated with mortality rates between 10% and 30%. Due to severe complications during therapeutic intervention, prevention strategies to combat pneumococcal meningitis (PM) are preferred. The vaccines available are so far suboptimal and inefficient to prevent serious PM. Hence, deciphering the mechanisms employed by pneumococci to encounter and survive in the cerebrospinal fluid (CSF) will pave the way for the development of new antimicrobial strategies. This work used an in vivo proteome-based approach to identify pneumococcal proteins expressed in the CSF during acute meningitis. This strategy identified a nutrient uptake system and regulatory system to be highly expressed in the CSF and being crucial for PM. Knocking out two of the highly in vivo expressed proteins (AliA and ComDE) in S. pneumoniae yields to a significant increase in survival and decrease in pathogen burden of infected mice. These host compartment specific expressed pneumococcal antigens represent promising candidates for antimicrobials or protein-based vaccines.

1 May 2018 in Journal of Proteomics
Verified
Journal Article
Closed access
CBClaus Bachert
Claus Bachert
GHG. Holtappels
G. Holtappels
MMMaia Merabishvili
Maia Merabishvili
TMT. Meyer
T. Meyer
AMA. Murr
A. Murr
FSFrank Schmidt
Frank Schmidt

13 March 2023 in Infection
Verified
Journal Article
Open access
PDF file
ASAnna Stoliaroff-Pepin
Anna Stoliaroff-Pepin
CPCaroline Peine
Caroline Peine
THTim Herath
Tim Herath
JLJohannes Lachmann
Johannes Lachmann
WHWiebke Hellenbrand
Wiebke Hellenbrand
THThomas Harder
Thomas Harder
Purpose: COViK, a prospective hospital-based multicenter case-control study in Germany, aims to assess the effectiveness of COVID-19 vaccines against severe disease. Here, we report vaccine effectiveness (VE) against COVID-19-caused hospitalization and intensive care treatment during the Omicron wave. Methods: We analyzed data from 276 cases with COVID-19 and 494 control patients recruited in 13 hospitals from 1 December 2021 to 5 September 2022. We calculated crude and confounder-adjusted VE estimates. Results: 21% of cases (57/276) were not vaccinated, compared to 5% of controls (26/494; p < 0.001). Confounder-adjusted VE against COVID-19-caused hospitalization was 55.4% (95% CI: 12–78%), 81.5% (95% CI: 68–90%) and 95.6% (95%CI: 88–99%) after two, three and four vaccine doses, respectively. VE against hospitalization due to COVID-19 remained stable up to one year after three vaccine doses. Conclusion: Three vaccine doses remained highly effective in preventing severe disease and this protection was sustained; a fourth dose further increased protection.